Understand your health.
Find your next step.

Understanding obesity as a chronic condition can change the way you approach treatment.

Biology is part of the story

The brain, gut, fat tissue, and other organs exchange signals that influence hunger, fullness, and energy use. Genes, medications, sleep, stress, and the food environment also matter. A plan that only asks you to “try harder” misses much of that picture.

Why maintaining weight loss can be difficult

After weight loss, appetite can increase and the body may use less energy. These adaptations help explain why maintaining a change can take ongoing support. Regain is a reason to reassess care, not a measure of your character.

Progress is more than a number

Weight is one useful measure. Blood pressure, glucose, sleep, strength, mobility, and how you feel in daily life may also help guide treatment. Your goals should reflect your health and what matters to you.

Bring this question to your next visit

“What might be influencing my weight, and how will we measure progress beyond the scale?” A long-term plan can combine nutrition, movement, behavioral support, medication when appropriate, and referral for other treatments.

Sources

• OMA Review Course for the 2026 ABOM Exam — Rajpal, PDF pp. 4–13
• OMA Review Course for the 2026 ABOM Exam — Weber, PDF pp. 5–7, 19–21

Five things to gather before a metabolic-health consultation.

Your timeline

Think about when weight changes began and what was happening then: a medication change, pregnancy, a new job, disrupted sleep, illness, or a period of stress. Approximate dates are enough.

Your current care

Bring medication and supplement names, previous treatments, recent laboratory results, and any home measurements your clinician has asked you to track. Include what helped, what did not, side effects, and cost or access barriers. Do not stop prescribed treatment to prepare for a visit.

Your everyday life

Describe your typical meals, cultural food preferences, schedule, movement, sleep, and sources of support. Food access, caregiving, pain, and work hours belong in the conversation.

Your concerns and goals

Tell your clinician about fatigue, snoring, eating that feels out of control, mood concerns, or changes in function. Choose one or two goals that would improve daily life, such as walking more comfortably or feeling steadier around meals.

A useful question

“What are our first priorities, and when will we review the plan?” Keep personal medical details for a secure clinical visit rather than a public website form.

Sources

• OMA Review Course for the 2026 ABOM Exam — Frederiksen, PDF pp. 4–30
• OMA Review Course for the 2026 ABOM Exam — Weber, PDF pp. 5–6, 14–16

What common metabolic-health tests can—and cannot—tell you.

Blood sugar and cholesterol

A1C reflects average blood sugar over roughly the preceding three months. Glucose testing provides another view of blood sugar. A lipid panel looks at cholesterol and triglycerides. Results help inform risk and follow-up when considered alongside your history.

Liver health

Liver tests may be part of an assessment. Normal liver enzymes do not rule out metabolic liver disease. Your clinician may recommend additional evaluation based on your risk, rather than relying on one number.

What about fasting insulin?

There is no single universally accepted clinical test threshold that diagnoses insulin resistance in everyone. An insulin value or online calculator should not become a stand-alone diagnosis. Your clinician considers the wider pattern.

More testing is not always better

Symptoms, medications, family history, and existing conditions help determine which tests are useful. A tailored evaluation may include other tests, but everyone does not need the same extensive panel.

Ask for a plan

“Which result changes our next step? When should it be checked again?” A clear explanation and a follow-up plan are more useful than chasing an isolated “optimal” number.

Sources

• OMA Review Course for the 2026 ABOM Exam — Lowe Clayton, PDF pp. 5–8, 16–17
• OMA Review Course for the 2026 ABOM Exam — Frederiksen, PDF pp. 23, 31–37
• NIDDK: The A1C Test & Diabetes.

Support nourishment, enjoyment, and consistency during weight management.

Start with a flexible plate

A practical starting point is vegetables, a protein source, and a portion of carbohydrate-rich food. Beans, fish, poultry, eggs, tofu, whole grains, and familiar family foods can all have a place. Adapt the pattern to your culture, preferences, budget, and medical needs.

Make nourishment a priority

Weight loss can include loss of lean tissue. Adequate protein and resistance activity are important parts of a plan to support muscle. Protein needs vary, particularly with kidney disease or other conditions; ask for a personal target rather than copying a number online.

If your appetite is lower

Pay attention to whether you are getting enough food and fluids. Let your care team know if nausea, early fullness, or vomiting makes eating difficult. A lower appetite does not mean your body no longer needs nutrients.

You do not need the most restrictive plan

Different eating patterns can work. Fasting is not necessary for everyone and may be unsuitable with certain medications or an eating-disorder history. Choose a plan you can sustain and review it as your needs change.

Try one small step

Choose one meal this week and plan a satisfying protein source and produce option. Notice what makes the meal practical. Bring that information to your next visit.

Sources

• OMA Review Course for the 2026 ABOM Exam — Shetye, PDF pp. 5–13, 18–23, 28–31
• OMA Review Course for the 2026 ABOM Exam — Bartfield, PDF p. 11

Movement supports health even when the scale is quiet.

Think beyond burning calories

Walking, dancing, swimming, cycling, and adapted movement can support fitness and everyday function. Strength work helps train the muscles you use to carry groceries, climb steps, and get up from a chair.

Start where you are

For adults, U.S. guidelines recommend 150–300 minutes of moderate aerobic activity weekly and muscle-strengthening activity on at least two days. These are goals to work toward, not an entry requirement. Short periods of activity count.

Make the plan fit your body

Pain, balance concerns, heart or lung disease, and your current fitness can change the safest starting point. Your clinician or a qualified exercise professional can help adapt movement. A chair-based routine or brief walk may be a useful beginning.

Pair movement with nourishment

During weight loss, discuss strength, function, and adequate nutrition—not just pounds lost. Tracking an activity that becomes easier can make progress visible.

Choose a repeatable action

Try a short movement break at a predictable time of day. Pick something you enjoy and can repeat. Build gradually rather than jumping into an intense program.

Sources

• OMA Review Course for the 2026 ABOM Exam — Rhodes, PDF pp. 5, 11–16, 21–27
• U.S. Physical Activity Guidelines: key recommendations.

A more supportive approach to habits, sleep, and stress.

Start with curiosity

An eating pattern often has a context: hunger, fatigue, stress, convenience, or a familiar cue. Noticing that context can be more useful than labeling the day “good” or “bad.”

Choose one specific experiment

For example: “On three workdays this week, I will take a five-minute walk after lunch.” Choose a realistic action, a time, and a way to check in. If the plan does not fit, change the plan.

Track what helps

A brief note about energy, sleep, or a habit may be enough. Tracking should support you. If weighing or food logging increases distress or restrictive behavior, tell your clinician and consider another approach.

Give recovery a place in the plan

A regular sleep schedule and a calming wind-down routine may help. Loud snoring, gasping during sleep, or persistent daytime sleepiness deserve medical attention. Sleep hygiene alone does not treat sleep apnea.

Support can be part of treatment

Eating that feels out of control, persistent anxiety, or significant distress may call for additional care. Asking for behavioral-health support is a useful treatment step, not a failure of motivation.

Sources

• OMA Review Course for the 2026 ABOM Exam — Bleistein, PDF pp. 4–7, 14–29, 30–35
• OMA Review Course for the 2026 ABOM Exam — Frederiksen, PDF pp. 14, 20–27

How to have a productive conversation when progress changes.

Look at the pattern

Body weight varies from day to day. A longer trend, your symptoms, and changes in daily function are more useful than one weigh-in. A plateau can reflect biological adaptation and changing energy needs.

Review the whole plan

Discuss medication access, side effects, nutrition, movement, sleep, stress, and other medicines that may influence weight. Do not stop or change a prescription on your own. Your clinician can help decide whether the current approach still fits.

Plan for maintenance early

Ongoing care may be needed to maintain benefits. In SURMOUNT-4, adults who completed an initial tirzepatide treatment period were randomized to continue treatment or switch to placebo. Over the next year, average weight rose in the withdrawal group and fell further in the continuation group. This does not tell us what every individual will experience, but it supports planning beyond initial weight loss.

A useful next question

“What can we adjust safely, and what benefits have we already gained?” Maintaining improvements in function or metabolic health can be meaningful progress.

Sources

• OMA Review Course for the 2026 ABOM Exam — Rajpal, PDF pp. 11–12
• OMA Review Course for the 2026 ABOM Exam — Weber, PDF pp. 19–21
• Aronne et al. SURMOUNT-4. JAMA, 2024.

Medication, procedures, and surgery can belong in the same conversation.

Treatment is individualized

Your health conditions, prior response, preferences, access, and treatment risks all matter. There is no single sequence that suits everyone. Lifestyle support can continue alongside medication or procedural care.

Ask about specialist evaluation

Metabolic and bariatric surgery and some endoscopic procedures are established options for selected people. Eligibility and the most suitable procedure require a specialist assessment. A referral is an opportunity to learn, not a commitment to surgery.

The follow-up matters

After a procedure, ongoing nutrition, vitamin and mineral monitoring, and clinical follow-up remain important. New symptoms or weight regain deserve assessment rather than blame.

Before a planned procedure

Tell the surgical and anesthesia teams about every medication, including GLP-1 or related treatment. Ask for individualized instructions about medicines, food, and fluids. Do not use a general website article as a medication-holding schedule.

Bring your priorities

“Which options best fit my health needs, and what ongoing care would each require?” Lakou can support an informed conversation; this education does not imply that Lakou performs these procedures.

Sources

• OMA Review Course for the 2026 ABOM Exam — Gómez, PDF pp. 4–24, 30–40, 59–72
• OMA Review Course for the 2026 ABOM Exam — Weber, PDF pp. 5–9

A caregiver resource for building a more supportive home.

Focus on care and connection

Children deserve respectful, developmentally appropriate care. Family meals, enjoyable activity, sleep routines, and access to nourishing food are useful shared priorities. Avoid singling out a child or turning body size into a moral judgment.

Keep the approach age-appropriate

Children are growing. Adult calorie targets, medication plans, and weight-loss goals should not be applied to them. A pediatric clinician assesses growth, health, development, and family context.

Seek support early

If you have concerns about a child’s growth, sleep, eating, or emotional well-being, discuss them with their pediatric clinician. Family-based programs and other treatments may be appropriate after assessment.

A family experiment

Choose a shared routine, such as an enjoyable movement break or a screen-free meal, that everyone can join. Make the goal connection and consistency.

About this resource

This is general caregiver education. It does not announce pediatric treatment at Lakou Health or replace a pediatric evaluation.

Sources

• OMA Review Course for the 2026 ABOM Exam — O’Hara, PDF pp. 26–35
• OMA Review Course for the 2026 ABOM Exam — Rhodes, PDF p. 21
• OMA Review Course for the 2026 ABOM Exam — Weber, PDF pp. 34–38

What current research means for a thoughtful weight-management conversation. Evidence checked October 1, 2026.

Start with the distinction

Semaglutide acts on GLP-1 receptors. Tirzepatide acts on both GIP and GLP-1 receptors. Newer approaches target additional pathways or offer oral treatment. A promising trial result is different from FDA approval, and approval does not establish that a medicine is right for every person.

Tirzepatide and semaglutide: a direct comparison

SURMOUNT-5 randomized 751 adults with obesity without diabetes. At 72 weeks, average weight reduction was 20.2% with tirzepatide versus 13.7% with semaglutide. The open-label trial used maximum tolerated weekly doses of 10 or 15 mg and 1.7 or 2.4 mg, respectively. Gastrointestinal effects were the most common adverse events. This comparison did not test oral semaglutide or the newer 7.2-mg injection. SURMOUNT-5

Oral options have expanded

Foundayo (orforglipron), an oral small-molecule GLP-1 medicine, received FDA approval in April 2026 for qualifying adults. In ATTAIN-1, the highest studied dose produced average weight reduction of 11.2% versus 2.1% with placebo at 72 weeks in adults without diabetes. Study doses and marketed formulations should not be used as self-dosing instructions. FDA Foundayo; ATTAIN-1

Oral and higher-dose semaglutide

Wegovy now has an FDA-approved tablet formulation. OASIS 4 studied oral semaglutide 25 mg in adults with overweight or obesity without diabetes: average weight reduction at 64 weeks was 13.6% versus 2.2% with placebo. Gastrointestinal side effects were more frequent with treatment. The FDA also approved a 7.2-mg weekly Wegovy injection in March 2026 for certain adults. Formulation, administration requirements, and tolerability matter. OASIS-4; Wegovy label; FDA Wegovy HD

CagriSema: investigational combination treatment

CagriSema combines semaglutide with the amylin analogue cagrilintide. In REDEFINE 1, 3,417 adults without diabetes were randomized across four groups. Average weight reduction at 68 weeks was 20.4% with the combination versus 3.0% with placebo in the treatment-policy analysis. Gastrointestinal adverse events occurred in 79.6% versus 39.9%, respectively. Cagrilintide is not currently a component of an FDA-approved drug; this is research education, not an available Lakou treatment. REDEFINE-1; FDA unapproved

Retatrutide: an investigational treatment in focus

Retatrutide targets GIP, GLP-1, and glucagon receptors. It remains investigational. The TRIUMPH-1 phase 3 publication appeared on September 29, 2026. Separately, Lilly’s September 29 TRIUMPH-2 report described 1,152 adults with type 2 diabetes and overweight or obesity: at 80 weeks, the highest studied dose showed 20.8% average weight reduction versus 4.0% with placebo in an analysis estimating continued treatment. Gastrointestinal effects were common; 7.7% at that dose stopped because of adverse events versus 4.9% with placebo. These figures come from the sponsor’s report, which states simultaneous Lancet publication; the full Lancet paper was not independently reviewed for this resource. FDA says retatrutide cannot be used in compounding. TRIUMPH-1; TRIUMPH-2; FDA unapproved

Health outcomes matter, too

In SELECT, adults aged 45 or older with established cardiovascular disease and overweight or obesity, without diabetes, had fewer major cardiovascular events with semaglutide than placebo: 6.5% versus 8.0% over a mean follow-up of about 40 months. This is a 1.5-percentage-point absolute difference and about a 20% relative risk reduction. The finding applies to that population; it is not proof of the same benefit for every drug or every patient. SELECT

Read the numbers in context

Different trials enroll different people, run for different lengths of time, and handle treatment discontinuation differently. “If treatment is continued” analyses can differ from analyses that include stopping treatment. These results are averages, not personal forecasts. Apart from the stated head-to-head study, this article does not rank the drugs against one another. The cited medication trials were industry-funded.

A balanced treatment conversation

GLP-1 and related medicines may cause nausea, vomiting, diarrhea, constipation, and sometimes serious adverse effects. Product-specific warnings and contraindications matter, including medullary thyroid cancer/MEN2 history for the approved medicines discussed here. Review pregnancy plans, other medicines, digestive symptoms, gallbladder or pancreatic history, and upcoming procedures with your prescriber. Severe or persistent abdominal pain, inability to keep fluids down, or signs of an allergic reaction need prompt medical attention. This summary does not replace the full prescribing information. Wegovy label; Foundayo label

What to ask your clinician

“Which option fits my medical history, goals, budget, and ability to continue treatment—and how will we monitor benefit and side effects?” New medication choices work best within a plan that includes nourishment, movement, and follow-up.

Sources

• Aronne et al. SURMOUNT-5. NEJM, 2025.
• Wharton et al. ATTAIN-1. NEJM, 2025.
• Oral semaglutide 25 mg: OASIS 4. NEJM, 2025.
• Cagrilintide–semaglutide: REDEFINE 1. NEJM, 2025.
• Retatrutide: TRIUMPH-1. NEJM, September 29, 2026.
• Lilly primary sponsor report: TRIUMPH-2, September 29, 2026.
• Lincoff et al. SELECT. NEJM, 2023.
• Aronne et al. SURMOUNT-4. JAMA, 2024.
• FDA: Foundayo approval, April 1, 2026.
• FDA prescribing information: Foundayo, 2026.
• FDA prescribing information: Wegovy injection and tablets, 2026.
• FDA: higher-dose Wegovy approval, March 19, 2026.
• FDA: concerns with unapproved GLP-1 drugs.